JP2012530487A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012530487A5 JP2012530487A5 JP2012515616A JP2012515616A JP2012530487A5 JP 2012530487 A5 JP2012530487 A5 JP 2012530487A5 JP 2012515616 A JP2012515616 A JP 2012515616A JP 2012515616 A JP2012515616 A JP 2012515616A JP 2012530487 A5 JP2012530487 A5 JP 2012530487A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- seq
- epitope
- binding portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 24
- 102000036639 antigens Human genes 0.000 claims 24
- 108091007433 antigens Proteins 0.000 claims 24
- 101000978766 Homo sapiens Neurogenic locus notch homolog protein 1 Proteins 0.000 claims 12
- 102000045609 human NOTCH1 Human genes 0.000 claims 12
- 125000000539 amino acid group Chemical group 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 238000010494 dissociation reaction Methods 0.000 claims 4
- 230000005593 dissociations Effects 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 238000012986 modification Methods 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21819309P | 2009-06-18 | 2009-06-18 | |
| US61/218,193 | 2009-06-18 | ||
| PCT/IB2010/052711 WO2010146550A1 (en) | 2009-06-18 | 2010-06-16 | Anti notch-1 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016004952A Division JP2016121162A (ja) | 2009-06-18 | 2016-01-14 | 抗ｎｏｔｃｈ−１抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012530487A JP2012530487A (ja) | 2012-12-06 |
| JP2012530487A5 true JP2012530487A5 (OSRAM) | 2013-08-01 |
| JP6059985B2 JP6059985B2 (ja) | 2017-01-11 |
Family
ID=42575817
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012515616A Expired - Fee Related JP6059985B2 (ja) | 2009-06-18 | 2010-06-16 | 抗ｎｏｔｃｈ−１抗体 |
| JP2016004952A Pending JP2016121162A (ja) | 2009-06-18 | 2016-01-14 | 抗ｎｏｔｃｈ−１抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016004952A Pending JP2016121162A (ja) | 2009-06-18 | 2016-01-14 | 抗ｎｏｔｃｈ−１抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9090690B2 (OSRAM) |
| EP (2) | EP3431501A1 (OSRAM) |
| JP (2) | JP6059985B2 (OSRAM) |
| KR (1) | KR101570898B1 (OSRAM) |
| CN (1) | CN102686610A (OSRAM) |
| AU (1) | AU2010261364B2 (OSRAM) |
| BR (1) | BRPI1011805A2 (OSRAM) |
| CA (1) | CA2765989C (OSRAM) |
| CO (1) | CO6480924A2 (OSRAM) |
| IL (1) | IL217066A0 (OSRAM) |
| MX (1) | MX337468B (OSRAM) |
| NZ (1) | NZ597611A (OSRAM) |
| PE (1) | PE20121494A1 (OSRAM) |
| PH (1) | PH12011502609B1 (OSRAM) |
| RU (1) | RU2011151287A (OSRAM) |
| SG (1) | SG176731A1 (OSRAM) |
| WO (1) | WO2010146550A1 (OSRAM) |
| ZA (1) | ZA201109282B (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2541726T3 (es) * | 2008-10-01 | 2015-07-23 | F. Hoffmann-La Roche Ag | Anticuerpos anti-Notch2 y métodos de uso |
| WO2010146550A1 (en) | 2009-06-18 | 2010-12-23 | Pfizer Inc. | Anti notch-1 antibodies |
| PH12012500574A1 (en) * | 2009-09-30 | 2012-10-22 | Genentech Inc | Notch1-antagonist-resistant cancer(s) using notch3 antagonists |
| JP6016800B2 (ja) | 2010-12-15 | 2016-10-26 | ワイス・エルエルシー | 抗ノッチ１抗体 |
| WO2012080891A1 (en) * | 2010-12-15 | 2012-06-21 | Rinat Neuroscience Corp. | Anti-notch-1 antibodies |
| BR112015010436A2 (pt) | 2012-11-07 | 2017-08-22 | Pfizer | Anticorpos anti-notch3 e conjugados anticorpo-fármaco |
| EP3113799A1 (en) * | 2014-03-07 | 2017-01-11 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer with notch1 antibodies |
| KR20170029490A (ko) | 2014-07-11 | 2017-03-15 | 제넨테크, 인크. | 노치 경로 억제 |
| WO2017205651A1 (en) * | 2016-05-25 | 2017-11-30 | The Trustees Of Columbia University In The City Of New York | Human notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and dll-notch signaling |
| US11555076B2 (en) | 2016-10-29 | 2023-01-17 | Genentech, Inc. | Anti-MIC antibodies and methods of use |
| EP3845559A4 (en) | 2018-08-31 | 2022-12-28 | Bloom Technology Corporation | ANTIBODIES FOR ADVANCED GLYCATION TERMINAL PRODUCTS AND THEIR USE |
| WO2024053742A1 (ja) | 2022-09-09 | 2024-03-14 | 国立大学法人 東京医科歯科大学 | コロナウイルス感染症の治療薬 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| GB8421551D0 (en) | 1984-08-24 | 1984-09-26 | Ici Plc | Water-soluble dye |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| AU3144193A (en) | 1991-11-21 | 1993-06-15 | Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5786158A (en) | 1992-04-30 | 1998-07-28 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
| US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| JP2698529B2 (ja) | 1993-04-06 | 1998-01-19 | 浜松ホトニクス株式会社 | イメージインテンシファイア装置 |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| EP1117778A2 (en) | 1998-10-02 | 2001-07-25 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Methods and compositions for inducing differentiation and apoptosis in cells that overexpress the notch protein |
| US20030035798A1 (en) | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| US7399633B2 (en) * | 2000-10-27 | 2008-07-15 | Fred Hutchinson Cancer Research Center | Methods for immortalizing cells |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| US20030148954A1 (en) * | 2001-11-02 | 2003-08-07 | Wisconsin Alumni Research Foundation | Agents and methods for modulating activator protein-1-mediated cellular processes |
| JP2005526701A (ja) | 2001-11-14 | 2005-09-08 | ロランティス リミテッド | 内科療法 |
| CN1930288B (zh) | 2002-04-09 | 2012-08-08 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
| US7666982B2 (en) | 2002-07-18 | 2010-02-23 | Masayasu Okochi | Notch-origin polypeptides and biomarkers and reagents using the same |
| CN101014364B (zh) | 2002-12-24 | 2012-01-18 | 里纳特神经系统学公司 | 抗ngf抗体及其使用方法 |
| US7282203B2 (en) | 2003-11-26 | 2007-10-16 | Health Research, Inc. | Use of NOTCH pathway interfering agents for treatment of plasma cell disorders |
| US20080220416A1 (en) | 2004-05-20 | 2008-09-11 | The Board Of Trustees Of The University Of Illinoi | Compositions for Inhibiting Cell Growth and Inducing Apoptosis in Cancer Cells and Methods of Use Thereof |
| US20070077245A1 (en) | 2004-08-04 | 2007-04-05 | The Brigham And Women's Hospital, Inc. | NOTCH mutations leading to increased receptor signaling |
| WO2006053063A2 (en) | 2004-11-05 | 2006-05-18 | The Regents Of The University Of California | Notch-1 assay to detect neurodegenerative diseases |
| HRP20110859T1 (hr) | 2004-12-21 | 2011-12-31 | Medimmune Limited | Protutijela usmjerena na angiopoietin-2 i njihova upotreba |
| CA2600908A1 (en) | 2005-03-04 | 2006-09-08 | The Hospital For Sick Children | Methods for cancer prognosis |
| US7100777B1 (en) * | 2005-07-07 | 2006-09-05 | Jui-Chien Kao | Hanger rack for hand tools |
| US20070072222A1 (en) | 2005-09-23 | 2007-03-29 | Franziska Boess | FABP4 as biomarker for toxic effect |
| US20090305310A1 (en) | 2005-11-22 | 2009-12-10 | University Of Vermont And State Agricultural College | Methods for Determining Notch Signaling and Uses Thereof |
| US20080241150A1 (en) | 2006-05-15 | 2008-10-02 | The Brigham And Women's Hospital, Inc. | Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1 |
| PL2032166T3 (pl) | 2006-06-13 | 2013-09-30 | Oncomed Pharm Inc | Kompozycje i sposoby diagnozowania i leczenia nowotworów |
| EP2134356A2 (en) | 2007-03-05 | 2009-12-23 | Board of Regents, The University of Texas System | Negative genetic regulation of cancer cell renewal in synergy with notch- or numb-specific immunotherapy |
| PE20090321A1 (es) * | 2007-06-04 | 2009-04-20 | Genentech Inc | Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica |
| US8119366B2 (en) | 2007-10-05 | 2012-02-21 | Trojan Technologies, Ltd. | Antennapedia-dominant negative mastermind-like construct |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US8834875B2 (en) | 2010-01-13 | 2014-09-16 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
| CN102316897B (zh) | 2008-07-08 | 2014-11-05 | 昂考梅德药品有限公司 | Notch结合剂和拮抗剂及其应用方法 |
| US20110286916A1 (en) | 2008-11-20 | 2011-11-24 | Jose Miguel Aste-Amezaga | Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use |
| WO2010146550A1 (en) | 2009-06-18 | 2010-12-23 | Pfizer Inc. | Anti notch-1 antibodies |
| PH12012500574A1 (en) | 2009-09-30 | 2012-10-22 | Genentech Inc | Notch1-antagonist-resistant cancer(s) using notch3 antagonists |
| JP6016800B2 (ja) | 2010-12-15 | 2016-10-26 | ワイス・エルエルシー | 抗ノッチ１抗体 |
| WO2012080891A1 (en) | 2010-12-15 | 2012-06-21 | Rinat Neuroscience Corp. | Anti-notch-1 antibodies |
-
2010
- 2010-06-16 WO PCT/IB2010/052711 patent/WO2010146550A1/en not_active Ceased
- 2010-06-16 PH PH1/2011/502609A patent/PH12011502609B1/en unknown
- 2010-06-16 RU RU2011151287/10A patent/RU2011151287A/ru not_active Application Discontinuation
- 2010-06-16 MX MX2011013717A patent/MX337468B/es active IP Right Grant
- 2010-06-16 NZ NZ597611A patent/NZ597611A/en not_active IP Right Cessation
- 2010-06-16 KR KR1020127001293A patent/KR101570898B1/ko not_active Expired - Fee Related
- 2010-06-16 EP EP18172657.1A patent/EP3431501A1/en not_active Withdrawn
- 2010-06-16 AU AU2010261364A patent/AU2010261364B2/en not_active Ceased
- 2010-06-16 PE PE2011002114A patent/PE20121494A1/es not_active Application Discontinuation
- 2010-06-16 CA CA2765989A patent/CA2765989C/en not_active Expired - Fee Related
- 2010-06-16 CN CN2010800367326A patent/CN102686610A/zh active Pending
- 2010-06-16 JP JP2012515616A patent/JP6059985B2/ja not_active Expired - Fee Related
- 2010-06-16 SG SG2011090800A patent/SG176731A1/en unknown
- 2010-06-16 EP EP10730230A patent/EP2443151A1/en not_active Withdrawn
- 2010-06-16 US US13/378,791 patent/US9090690B2/en active Active
- 2010-06-16 BR BRPI1011805A patent/BRPI1011805A2/pt not_active IP Right Cessation
-
2011
- 2011-12-15 ZA ZA2011/09282A patent/ZA201109282B/en unknown
- 2011-12-18 IL IL217066A patent/IL217066A0/en unknown
- 2011-12-22 CO CO11177186A patent/CO6480924A2/es active IP Right Grant
-
2016
- 2016-01-14 JP JP2016004952A patent/JP2016121162A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012530487A5 (OSRAM) | ||
| JP2015504421A5 (OSRAM) | ||
| JP2013506428A5 (OSRAM) | ||
| JP2020508655A5 (OSRAM) | ||
| JP2009225799A5 (OSRAM) | ||
| JP2012525829A5 (OSRAM) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2012531922A5 (ja) | Ｔｏｌｌ様受容体２へのヒト化抗体またはその抗原結合部位 | |
| JP2019532619A5 (OSRAM) | ||
| JP2013545455A5 (OSRAM) | ||
| JP2012522523A5 (OSRAM) | ||
| JP2017504578A5 (OSRAM) | ||
| RU2012142231A (ru) | Антитела против csf-1r человека и их применение | |
| RU2017137010A (ru) | Анти-сеасам6 антитела и их применения | |
| RU2017123549A (ru) | Антитела, нацеленные на антиген созревания в-клеток, и способы их применения | |
| JP2018121657A5 (OSRAM) | ||
| JP2018522888A5 (OSRAM) | ||
| RU2011151287A (ru) | АНТИ Notch-1 АНТИТЕЛА | |
| JP2017149720A5 (OSRAM) | ||
| JP2014526898A5 (OSRAM) | ||
| JP2013198490A5 (OSRAM) | ||
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| JP2018516853A5 (OSRAM) | ||
| JP2011207882A5 (OSRAM) | ||
| RU2014122990A (ru) | Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas |